Solventum Co. (NYSE:SOLV) Stock Holdings Raised by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA raised its stake in Solventum Co. (NYSE:SOLV - Free Report) by 16.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 87,028 shares of the company's stock after purchasing an additional 12,437 shares during the quarter. Pictet Asset Management Holding SA owned about 0.05% of Solventum worth $5,749,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Modus Advisors LLC acquired a new position in Solventum in the fourth quarter valued at $25,000. Stonebridge Financial Group LLC purchased a new position in shares of Solventum in the 4th quarter worth about $26,000. Crews Bank & Trust acquired a new position in shares of Solventum in the 4th quarter valued at about $32,000. Synergy Asset Management LLC purchased a new stake in shares of Solventum during the 4th quarter worth about $35,000. Finally, Spire Wealth Management acquired a new stake in Solventum during the 4th quarter worth approximately $37,000.

Solventum Stock Down 3.5 %

SOLV traded down $2.28 on Tuesday, reaching $63.04. The company's stock had a trading volume of 1,346,822 shares, compared to its average volume of 1,353,061. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92. The business's 50 day moving average is $74.76 and its 200 day moving average is $71.78. The stock has a market cap of $10.91 billion and a price-to-earnings ratio of 22.92.

Wall Street Analysts Forecast Growth

SOLV has been the topic of a number of recent research reports. Wells Fargo & Company lifted their price target on shares of Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research report on Friday, February 28th. The Goldman Sachs Group upped their price target on shares of Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a research report on Monday, March 3rd. Piper Sandler raised their price objective on Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a research report on Friday, February 28th. Morgan Stanley upped their target price on Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th. Finally, Mizuho raised their target price on Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.